About the Authors
- Matt Kaeberlein
-
*To whom correspondence should be addressed. E-mails: kaeber@u.washington.edu (MK); bkenn@u.washington.edu (BKK)
- Christopher R Burtner
- Brian K Kennedy
-
*To whom correspondence should be addressed. E-mails: kaeber@u.washington.edu (MK); bkenn@u.washington.edu (BKK)
Competing Interests
BKK and MK have a pending patent application for technology for the identification of new aging genes. BKK has a minor stock holding in Elixir Pharmaceuticals.